This inventor holds 4 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2016-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Perkiomenville, PA (US) (2016)
- Audubon, PA (US) (2018 - 2021)
- Norristown, PA (US) (2024)
Company Filing History:
Years Active: 2016-2024
Title: Paul A Harmon: Innovator in Pharmaceutical Formulations
Introduction
Paul A Harmon is a notable inventor based in Audubon, PA (US), recognized for his contributions to pharmaceutical formulations. With a total of four patents to his name, Harmon has made significant strides in the field of drug development, particularly focusing on orexin receptor antagonists.
Latest Patents
Harmon’s latest patents include innovative solid dosage formulations of an orexin receptor antagonist. The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. This formulation aims to improve the efficacy and delivery of the medication, showcasing Harmon’s commitment to advancing pharmaceutical science.
Career Highlights
Throughout his career, Harmon has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Cephalon, Inc. His experience in these organizations has undoubtedly contributed to his expertise and success as an inventor.
Collaborations
Harmon has collaborated with several professionals in his field, including Narayan Variankaval and Michael Lowinger. These partnerships have likely enriched his work and led to innovative solutions in pharmaceutical formulations.
Conclusion
Paul A Harmon stands out as a significant figure in the realm of pharmaceutical inventions, particularly with his work on orexin receptor antagonists. His contributions continue to impact the industry positively, and his patents reflect his dedication to improving drug formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
